Concanavalin A Induces Patching/Capping of the Platelet Membrane Glycoprotein llb/llla Complex

Summary

Two recent reports have shown platelet patching/capping by concanavalin A (Con A). In these studies, Con A receptors were shown to mobilize from pseudopodia and lamellipodia to the central cell parts during platelet attachment and spreading. The molecular mechanism underlying Con A receptor capping was not examined in either study.

Con a binds maximally to human platelet membrane glycoproteins IIb and IIIa. In order to test whether Con A-induced capping caused the capping of this membrane glycoprotein complex, we treated normal human platelets with unlabeled Con A. After fixation, platelets were further treated with mouse monoclonal antibodies against the membrane glycoprotein IIb/IIIa complex and stained with fluorescein isothiocyanate (FITC) tagged anti-mouse IgG. An average of 16% platelets manifested capping with one monoclonal antibody preparation (N = 2) and 12% with a second preparation (N = 2).

Control studies showed that only 18% of normal human fresh platelets exhibit capping with FITC-Con A (N = 17). If platelets were first incubated with unlabeled Con A, followed by staining with FITC-labeled anti-Con A antibody, an average of 15% platelets manifested caps (N = 17). Capping was inhibited by methyl-alpha-D-mannopyranoside (a known inhibitor of Con A), at cold temperature and by pre-treatment of platelets with colchicine.

Our studies confirm the earlier findings on Con A induced capping. Also, our findings suggest that the molecular mechanism for Con A receptor capping involves patching and capping of the platelet membrane glycoprotein IIb/IIIa complex. It is possible that glycoprotein Ilb/IIIa redistribution might be intimately involved during platelet attachment and spreading.

Keywords

Platelet capping - Concanavalin A - Platelet glycoproteins - Lectin

• References

• 1 Alexandrova AY, Vasiliev JM. Capping of cross-linked Concanavalin A receptors on the surface of substrate-spread platelets. Cell Motility 1982; 2: 163-163
• 2 Bourguignon LY W. Receptor capping in platelet membranes. Cell Biol Internal Rep 1984; 8: 19-19
• 3 McGregor JL, Clemetson KJ, James E, Greenland T, Dechvanne M. Identification of human platelet glycoproteins in SDS polyacrylamide gels using ¹²⁵ I-labeled lectins. Thromb Res 1979; 16: 825-825
• 4 Santoso S, Zimmerman V, Boschek B, Neppert J, Mueller-Eckhardt C. Patching and capping of platelet membrane glycoproteins Ilb/IIIa and lb induced by monoclonal antibodies. Blut 1984; 49: 286-286
• 5 Wheeler ME, Cox AC, Carroll RC. Retention of the glycoprotein Ilb/IIIa complex in the isolated platelet cytoskeleton. Effects of separable assembly of platelet pseudopodal and contractile cytoskeletons. J Clin Invest 1984; 74: 1080-1080
• 6 Zucker MB, Masiello NC. The Triton-X-100-insoluble residue (“cytoskeleton”) of aggregated platelets contains increased lipid phosphorus as well as ¹²⁵I-labeled glycoproteins. Blood 1983; 61: 676-676
• 7 Painter RG, Ginsberg M, Jaques B. Concanavalin A induces interactions between surface glycoproteins and the platelet cytoskeleton. J Cell Biol 1982; 92: 565-565
• 8 Firkin BG, Hendrix L, Goh A. An investigation of thrombasthenic platelets with selected lectins. Thromb Res 1978; 13: 337-337
• 9 Menche D, Israel A, Karpatkin S. Platelets and microtubules. Effects of Colchicine and D₂O on platelet aggregation and release induced by calcium ionophore A23187. J Clin Invest 1980; 66: 284-284
• 10 Bittiger H, Schnebli HP. (eds) Concanavalin A as a tool. John Wiley & Sons. New York: 1976
• 11 Johnston GI, Heptinstall S, Robins RA, Price MR. The expression of glycoproteins on single blood platelets from healthy individuals and from patients with congenital bleeding disorders. Biochem Biophys Res Commun 1984; 123: 1091-1091